Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct;14(10):2739-2757.
doi: 10.1007/s13555-024-01255-4. Epub 2024 Sep 24.

Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence

Piergiorgio Malagoli  1 , Paolo Dapavo  2 , Paolo Amerio  3 , Laura Atzori  4 , Anna Balato  5 , Federico Bardazzi  6 , Luca Bianchi  7 , Angelo Cattaneo  8 , Andrea Chiricozzi  9 , Maurizio Congedo  10 , Maria Concetta Fargnoli  11 , Claudia Giofrè  12 , Paolo Gisondi  13 , Claudio Guarneri  14 , Serena Lembo  15 , Francesco Loconsole  16 , Giampiero Mazzocchetti  17 , Santo Raffaele Mercuri  18 , Pietro Morrone  19 , Anna Maria Offidani  20 , Giovanni Palazzo  21 , Aurora Parodi  22 , Giovanni Pellacani  23 , Stefano Piaserico  24 , Concetta Potenza  25   26 , Francesca Prignano  27 , Marco Romanelli  28 , Paola Savoia  29 , Luca Stingeni  30 , Massimo Travaglini  31 , Emanuele Trovato  32 , Marina Venturini  33 , Leonardo Zichichi  34 , Antonio Costanzo  35   36
Affiliations
Review

Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence

Piergiorgio Malagoli et al. Dermatol Ther (Heidelb). 2024 Oct.

Abstract

Psoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to-severe plaque psoriasis. Secukinumab, a fully humanized monoclonal antibody, was the first anti-interleukin (IL)-17 biologic approved for treating psoriasis. Secukinumab demonstrated long-lasting efficacy and a good safety profile in individuals with plaque psoriasis, and it is associated with an improvement in health-related quality of life. While there is evidence that early treatment with systemic therapy can affect disease progression and improve long-term outcomes in other autoimmune diseases, evidence is limited in psoriasis, especially in real-world settings. This review provides an overview of studies describing the effectiveness of secukinumab in the treatment of psoriasis summarizing the literature and focusing on real-world evidence and early intervention.

Keywords: Early treatment; Psoriasis; Secukinumab; Treatment.

PubMed Disclaimer

Conflict of interest statement

Paolo Amerio declares the following conflicts of interest: Novartis, Sanofi, Jannsen, Eli Lilly, Galderma. Laura Atzori has been consultant, PI, speaker for Abbvie, Novartis, Janssen, UCB Pharma, Sanofi Genzyme, Lilly, Pfizer, Almirall, BMS. Anna Balato has served on Scientific Boards and/or has received fees for Scientific Consultations from: Abbvie, Amgen, Boehringer Ingelheim, Janssen, Eli-Lilly, Novartis, UCB. Luca Bianchi has been consultant, PI, speaker for Abbvie, Novartis, Janssen, UCB Pharma, Sanofi Genzyme, Lilly, Pfizer, Almirall, Sun Pharma, BMS. Andrea Chiricozzi has served as advisory board member and consultant and has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Bristol Myers Squibb, Leo Pharma, Lilly, Janssen, Novartis, Pfizer and Sanofi Genzyme. Antonio Costanzo has been principal investigator in clinical trials sponsored by and/or and has received personal fees for participation in advisory board from Abbvie, Almirall, Amgen, Boehringer, BMS, Leo Pharma, Lilly, Novartis, Pfizer, UCB and Sanofi, outside the submitted work. Maria Concetta Fargnoli has served on advisory boards, received honoraria for lectures and/or research grants from AMGEN, Almirall, Abbvie, Boehringer-Ingelheim, BMS, Galderma, Kyowa Kyrin, Leo Pharma, Pierre Fabre, UCB, Lilly, Pfizer, Janssen, MSD, Novartis, Sanofi-Regeneron, Sunpharma. Claudia Giofrè has served as advisory board member or has received fees and speaker or has participated in clinical trials for Amgen, Novartis, Janssen, Leo Pharma, Almirall, Abbvie, UCB, Lilly. Paolo Gisondi declares the following conflicts of interest: Amgen, Almirall Abbvie Eli Lilly Novartis Janssen UCB Pierre Fabre Pfizer. Claudio Guarneri declares the following conflicts of interest: Pfizer, Abbvie, Janssen, Novartis, Merck-Serono, Eli-Lilly, Celgene, Leo Pharma, Leo Pharma Denmark, Almirall, Amgen, Sanofi-Aventis, Boehringer-Ingelheim, Bristol Myers Squibb, UCB Pharma. Serena Lembo declares the following conflicts of interest: Pfizer, Abbvie, Janssen, Novartis, Eli-Lilly, Leo Pharma, Almirall, Sanofi-Aventis, UCB Pharma. Santo Raffaele Mercuri SRM has been principal investigator in clinical trials sponsored by and/or has received personal fees for participation in advisory board from Abbvie, Almirall, Amgen, Leopharma, Lilly, Jansenn, Novartis, Sanofi and Ucb, outside the submitted work. Pietro Morrone has served as advisory board member or has received fees and speaker for AbbVie, Almirall,Novartis, Sanofi Genzyme, Lilly, Leo Pharma. Giovanni Palazzo declares the following conflicts of interest: Novartis, Abbvie, Leopharma, Lilly, Pfizer, Janssen. Aurora Parodi declares the following conflicts of interest: Almirall, Abbvia, Amgen, Novartis, Pfizer, Lilly, LEO pharma, Euroimmun, Argx, Menarini, Boehringer. Giovanni Pellacani received institutional grants and/or honoraria for Advisory boards: Abbvie, Galderma, Leo-pharma, Lilly, Pfizer, Novartis, Sanofi, UCB. Stefano Piaserico has been a consultant and/or speaker for Abbvie, Almirall, Amgen, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, andUCB. Francesca Prignano served as consultant, presenter and advisory board member for Abbvie, Novartis, Eli-Lilly, Jannsen-Cilag, Bohringer- Ingelheim, Almirall, Leo-Pharma, UCB, Bristol-Meyers-Squibb. Marco Romanelli: Abbvie, Lilly, Novartis, URGO, ConvaTec. Paola Savoia has served as advisory board member or has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Bristol Myers Squibb, Ganassini, Kyowa Kirin, Janssen, Novartis, Sanofi and Sunpharma. Luca Stingeni has been principal investigator in clinical trials sponsored by and/or and has received personal fees for participation in advisory board from Abbvie, Leo Pharma, Lilly, Novartis, Pfizer, and Sanofi, outside the submitted work. Emanuele Trovato: Speaker for Abbvie, Novartis, Janssen, UCB Pharma, Eli-Lilly, Almirall, Leo Pharma. Marina Venturini has served as advisory board member and consultant and has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Bristol Myers Squibb, Boehringer-Ingelheim, Eli Lilly, Galderma, Janssen, Leo Pharma, Novartis, Pierre Fabre, UCB Pharma. Leonardo Zichichi has been consultant, and speaker for Abbvie, Novartis, Janssen, Sanofi Genzyme, Lilly, Almirall, Sun Pharma.

References

    1. Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of psoriasis and comorbid diseases: a narrative review. Front Immunol. 2022;10:13. - PMC - PubMed
    1. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2013;133(2):377–85. - PubMed
    1. de Oliveira MFSP, Rocha BO, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20. - PMC - PubMed
    1. Noe MH, Shin DB, Wan MT, Gelfand JM. Objective measures of psoriasis severity predict mortality: a prospective population-based cohort study. J Investig Dermatol. 2018;138(1):228–30. - PMC - PubMed
    1. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4(1):35. - PMC - PubMed

LinkOut - more resources